Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force

다국어 초록 (Multilingual Abstract)

Pheochromocytoma and paraganglioma (PPGLs) are rare catecholamine-secreting neuroendocrine tumors but can be life-threatening. Although most PPGLs are benign, approximately 10% have metastatic potential. Approximately 40% cases are reported as harboring germline mutations. Therefore, timely and accurate diagnosis of PPGLs is crucial. For more than 130 years, clinical, molecular, biochemical, radiological, and pathological investigations have been rapidly advanced in the field of PPGLs. However, performing diagnostic studies to localize lesions and detect metastatic potential can be still challenging and complicated. Furthermore, greatprogress on genetics has shifted the paradigm of genetic testing of PPGLs. The Korean PPGL task force team consisting of the Korean Endocrine Society, the Korean Surgical Society, the Korean Society of Nuclear Medicine, the Korean Society of Pathologists, andthe Korean Society of Laboratory Medicine has developed this position statement focusing on the comprehensive and updated diagnosis for PPGLs.

참고문헌 (Reference)

1 서수현, "Whole Exome Sequencing Identifies Novel Genetic Alterations in Patients with Pheochromocytoma/Paraganglioma" 대한내분비학회 35 (35): 909-917, 2020

2 DeLellis RA, "WHO classification of tumours: pathology and genetics of tumours of endocrine organs" IARC 2004

3 Lloyd RV, "WHO classification of tumours: pathology and genetics of tumours of endocrine organs" IARC Press 2017

4 Milardovic R, "Value of 123IMIBG scintigraphy in paraganglioma" 91 : 94-100, 2010

5 Koh JM, "Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma" 12 : e0187398-, 2017

6 Wiseman GA, "Usefulness of 123IMIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma : results from a prospective multicenter trial" 50 : 1448-1454, 2009

7 Pillai S, "Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era" 100 : 190-208, 2016

8 Lam AK, "Update on adrenal tumours in 2017 World Health Organization(WHO)of endocrine tumours" 28 : 213-227, 2017

9 Adjalle R, "Treatment of malignant pheochromocytoma" 41 : 687-696, 2009

10 Stenman A, "The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas: a metaanalysis and systematic review of the literature" 11 : 225-, 2019

11 Wang Y, "The systems of metastatic potential prediction in pheochromocytoma and paraganglioma" 10 : 769-780, 2020

12 Grossrubatscher E, "The role of chromogranin A in the management of patients with phaeochromocytoma" 65 : 287-293, 2006

13 Brito JP, "Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review" 82 : 338-345, 2015

14 Ben Aim L, "Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma" 56 : 513-520, 2019

15 Cho YY, "Symptom-dependent cut-offs of urine metanephrines improve diagnostic accuracy for detecting pheochromocytomas in two separate cohorts, compared to symptom-independent cut-offs" 54 : 206-216, 2016

16 Janssen I, "Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma" 21 : 3888-3895, 2015

17 Amar L, "Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas" 92 : 3822-3828, 2007

18 Agarwal A, "Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?" 34 : 3022-3028, 2010

19 Pillai S, "Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma : a clinicopathological correlations" 102 : 41-46, 2017

20 Lumachi F, "Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas : a prospective study" 27 : 583-587, 2006

21 Papathomas TG, "SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas : a multicenter interobserver variation analysis using virtual microscopy. A multinational study of the European Network for the Study of Adrenal Tumors(ENS@T)" 28 : 807-821, 2015

22 Pasini B, "SDH mutations in tumorigenesis and inherited endocrine tumours : lesson from the phaeochromocytoma-paraganglioma syndromes" 266 : 19-42, 2009

23 Kimura N, "Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine" 7 : 242-, 2018

24 Kulkarni MM, "Risk stratification in paragangliomas with PASS(Pheochromocytoma of the Adrenal Gland Scaled Score)and immunohistochemical markers" 10 : EC01-4-, 2016

25 Lee H, "Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers : a systematic review and updated meta-analysis" 57 : 217-225, 2020

26 van Hulsteijn LT, "Quality of life is decreased in patients with paragangliomas" 168 : 689-697, 2013

27 Archier A, "Prospective comparison of(68)Ga-DOTATATE and(18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases" 43 : 1248-1257, 2016

28 Wachtel H, "Predicting metastatic potential in pheochromocytoma and paraganglioma : a comparison of PASS and GAPP scoring systems" 105 : e4661-70, 2020

29 Buffet A, "Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma" 104 : 1109-1118, 2019

30 Rao D, "Plasma methoxytyramine : clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma" 177 : 103-113, 2017

31 Eisenhofer G, "Plasma methoxytyramine : a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status" 48 : 1739-1749, 2012

32 Hickman PE, "Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma" 41 : 173-177, 2009

33 Algeciras-Schimnich A, "Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma" 93 : 91-95, 2008

34 Unger N, "Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass" 120 : 494-500, 2012

35 Pacak K, "Pheochromocytoma(PHEO)and paraganglioma(PGL)" 11 : 1391-, 2019

36 Beltsevich DG, "Pheochromocytoma surgery : epidemiologic peculiarities in children" 28 : 592-596, 2004

37 Thompson LD, "Pheochromocytoma of the Adrenal gland Scaled Score(PASS)to separate benign from malignant neoplasms : a clinicopathologic and immunophenotypic study of 100 cases" 26 : 551-566, 2002

38 Lenders JW, "Pheochromocytoma and paraganglioma : an endocrine society clinical practice guideline" 99 : 1915-1942, 2014

39 Neumann HPH, "Pheochromocytoma and paraganglioma" 381 : 552-565, 2019

40 Welch TJ, "Pheochromocytoma : value of computed tomography" 148 : 501-503, 1983

41 Han S, "Performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma : a systematic review and metaanalysis" 60 : 369-376, 2019

42 Satapathy S, "Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis" 91 : 718-727, 2019

43 Kimura N, "Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma" 21 : 405-414, 2014

44 Favier J, "Paraganglioma and phaeochromocytoma : from genetics to personalized medicine" 11 : 101-111, 2015

45 Janssen I, "PET/CT comparing(68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma" 43 : 1784-1791, 2016

46 Gieldon L, "Optimizing genetic workup in pheochromocytoma and paraganglioma by integrating diagnostic and research approaches" 11 : 809-, 2019

47 Plouin PF, "Metastatic pheochromocytoma and paraganglioma : focus on therapeutics" 44 : 390-399, 2012

48 Timmers HJ, "Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma" 15 : 1127-1133, 2008

49 Angelousi A, "Malignant pheochromocytomas/paragangliomas and ectopic hormonal secretion: a case series and review of the literature" 11 : 724-, 2019

50 Roman-Gonzalez A, "Malignant pheochromocytoma-paraganglioma : pathogenesis, TNM staging, and current clinical trials" 24 : 174-183, 2017

51 Szalat A, "Malignant pheochromocytoma : predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center" 39 : 160-166, 2011

52 Lenders JW, "Is supine rest necessary before blood sampling for plasma metanephrines?" 53 : 352-354, 2007

53 Maurea S, "Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas : comparison with CT and MRI" 34 : 173-179, 1993

54 van Gils AP, "Iodine-123-metaiodobenzylguanidine scintigraphy in patients with chemodectomas of the head and neck region" 31 : 1147-1155, 1990

55 Berends AMA, "Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands : a nationwide study and systematic review" 51 : 68-73, 2018

56 Gimenez-Roqueplo AP, "Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers : a multicenter prospective study from the PGL. EVA Investigators" 98 : E162-73, 2013

57 Brouwers FM, "High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas : implications for genetic testing" 91 : 4505-4509, 2006

58 Kim JH, "Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea" 86 : 482-486, 2014

59 Jochmanova I, "Genomic landscape of pheochromocytoma and paraganglioma" 4 : 6-9, 2018

60 Muth A, "Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma" 285 : 187-204, 2019

61 최희원, "Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population" 대한내분비학회 35 (35): 858-872, 2020

62 Janssen I, "Functional imaging signature of patients presenting with polycythemia/paraganglioma syndromes" 58 : 1236-1242, 2017

63 Fonte JS, "False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease" 19 : 83-93, 2012

64 Plouin PF, "European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma" 174 : G1-10, 2016

65 Taieb D, "European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma" 46 : 2112-2137, 2019

66 김정희, "Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service" 대한내분비학회 35 (35): 157-164, 2020

67 Pryma DA, "Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma" 60 : 623-630, 2019

68 Kim KY, "Disentangling of malignancy from benign pheochromocytomas/paragangliomas" 11 : e0168413-, 2016

69 Unger N, "Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass" 154 : 409-417, 2006

70 Kim HJ, "Diagnostic accuracy of plasma free metanephrines in a seated position compared with 24-hour urinary metanephrines in the investigation of pheochromocytoma" 62 : 243-250, 2015

71 Grouzmann E, "Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma" 162 : 951-960, 2010

72 김정희, "Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology" 대한내분비학회 35 (35): 272-287, 2020

73 Jimenez C, "Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma" 15 : 356-371, 2013

74 NGS in PPGL(NGSnPPGL)Study Group, "Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas" 13 : 233-247, 2017

75 Rufini V, "Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma : a systematic review" 57 : 122-133, 2013

76 Ilias I, "Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma" 49 : 1613-1619, 2008

77 Ayala-Ramirez M, "Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas : primary tumor size and primary tumor location as prognostic indicators" 96 : 717-725, 2011

78 Goldstein RE, "Clinical experience over 48 years with pheochromocytoma" 229 : 755-764, 1999

79 Choi YM, "Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma : a single institution experience" 112 : 815-821, 2015

80 Barontini M, "Characteristics of pheochromocytoma in a 4-to 20-year-old population" 1073 : 30-37, 2006

81 Jung Hee Kim, "Characteristics of germline mutations in Korean patients with pheochromocytoma/paraganglioma" BMJ 59 (59): 56-64, 2022

82 Kvasnicka J, "Catecholamines induce left ventricular subclinical systolic dysfunction: a speckle-tracking echocardiography study" 11 : 318-, 2019

83 Eisenhofer G, "Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma" 18 : 97-111, 2010

84 Pierre C, "COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas" 474 : 721-734, 2019

85 Ballal S, "Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT : first clinical experience on the efficacy and safety" 47 : 934-946, 2020

86 Ayala-Ramirez M, "Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma" 98 : 1492-1497, 2013

87 Timmers HJ, "Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene" 93 : 4826-4832, 2008

88 Lenders JW, "Biochemical diagnosis of pheochromocytoma: which test is best?" 287 : 1427-1434, 2002

89 Eisenhofer G, "Biochemical and clinical manifestations of dopamine-producing paragangliomas : utility of plasma methoxytyramine" 90 : 2068-2075, 2005

90 Bisogni V, "Analysis of short-term blood pressure variability in pheochromocytoma/paraganglioma patients" 11 : 658-, 2019

91 Buffet A, "An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma" 34 : 101416-, 2020

92 van Nederveen FH, "An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations : a retrospective and prospective analysis" 10 : 764-771, 2009

93 Edge SB, "American Joint Committee on Cancer. AJCC cancer staging manual" Springer 2017

94 Chen Y, "Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma : a systematic review and meta-analysis" 23 : 1169-1177, 2017

95 MacFarlane J, "A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: beyond phaeochromocytoma and paraganglioma" 93 : 528-538, 2020

96 Kroiss A, "A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma" 40 : 1800-1808, 2013

97 Cho YY, "A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma : ASES score" 164 : 511-517, 2018

98 Janssen I, "68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI" 57 : 186-191, 2016

99 Fiebrich HB, "6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess" 94 : 3922-3930, 2009

100 Taieb D, "18F-FDOPA PET/CT imaging of MAX-related pheochromocytoma" 103 : 1574-1582, 2018

101 Bhatia KS, "123I-metaiodobenzylguanidine (MIBG)scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation" 69 : 181-188, 2008

102 Vyakaranam AR, "11C-hydroxy-ephedrine-PET/CT in the diagnosis of pheochromocytoma and paraganglioma" 11 : 847-, 2019

103 Kroiss A, "(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to(123)I-MIBG SPECT/CT" 42 : 33-41, 2015

104 Chang CA, "(68)Ga-DOTATATE and(18)F-FDG PET/CT in paraganglioma and pheochromocytoma : utility, patterns and heterogeneity" 16 : 22-, 2016

105 van Hulsteijn LT, "(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis" 80 : 487-501, 2014